MIDDLETOWN, Pa.—MacuLogix, Inc., has entered into an international distribution agreement with Clarion Medical Technologies, according to an announcement from MacuLogix. Clarion, the leading Canadian provider of medical and aesthetic equipment, will add the AdaptDx automated dark adaptometer to its vision division’s portfolio of products. MacuLogix provides eyecare professionals with the tools and educational products to successfully diagnose and treat patients for AMD, the leading cause of adult blindness. “We are very pleased to partner with Clarion to expand our reach into Canada,” said Armond Dantino, vice president of sales for MacuLogix.

“Bringing the AdaptDx to Canada is critical to preserving vision, as AMD accounts for 90 percent of new cases of legal blindness in Canada, according to the Canadian Ophthalmological Society.”

The AdaptDx is the first commercially available dark adaptometer that can be used in clinical practice to detect AMD at a subclinical stage, before structural changes in the retina, like drusen, become visible. The companies research shows that functional assessment of dark adaptation using the AdaptDx can radically improve diagnostic sensitivity and specificity by detecting the disease with 90 percent accuracy at least three years before structural changes such as drusen are visible, enabling clinicians to intervene before irreversible vision loss occurs.

Dan Webb, chairman of Clarion Medical Technologies said, "We take great pride in offering cutting-edge technology solutions to our vision customers and are confident that Canadian eyecare professionals will find great value in the AdaptDx for detecting and monitoring age-related macular degeneration."